*Read Disclaimer Sponsored Content
{{current_date_full}} | Unsubscribe
Hello!
New Alert: BioStem Technologies Inc. (NASDAQ: BSEM)
BSEM is our brand new Nasdaq high growth alert.
This is a hidden gem opportunity that almost no one has seen yet.
The company just started trading on the NASDAQ last week.
BSEM has a big breakout opportunity developing.
BSEM is a NASDAQ listed “leading regenerative medicine company”.
BSEM is a “biomedical innovator, focused on developing, manufacturing and commercializing advanced allograft solutions derived from perinatal tissue”.
The company “leverages its industry-leading proprietary BioRetain®, CryoTek® and SteriTek® processing technologies, designed to optimize the preservation of the natural properties of these tissues, supporting their use in clinical settings.”
Its “allografts are used by clinicians across a wide range of specialties.”
BSEM is targeting one of the largest and most underserved segments in medical technology.
The company’s mission is “To create and deliver the most advanced wound healing technologies in the world” – “In Relentless Pursuit of Healing”.
The opportunity here is substantial.
BSEM is pursuing a “Large and Underserved ~$23B US Soft Tissue Allograft Opportunity” by “Driving adoption of perinatal tissue allografts for multiple market segments”.
That 23 billion market spans six segments:
Orthopedics/Sports Medicine
Chronic Wound Care
Foot & Ankle
Urology/ Colorectal
Spine
Women’s Health
The clinical and economic need is severe.
Sadly, there are approximately “155,000 lower limb amputations annually” and approximately “800,000 DFU hospitalizations annually”.
Infections and complications “cost the health system an estimated $30B+ each year”.
Perinatal Allografts address this by promoting faster healing, minimizing scarring and adhesion, preventing infection, pain management and reducing complications versus standard of care.
BSEM's has these advantages:
“Experienced National Sales Force” with “> 25 direct reps and >30 independent agents plus GPO contracts”
“Unparalleled Technical Data” with “400+ publications across all technologies and products”
“World-Class Manufacturing Capabilities” with “Experienced in-house manufacturing with ability to scale and produce historically industry leading margins”
“Expanded Addressable Market” with “End markets now include surgical applications in facility settings, including commercially insured population”
With a “growing portfolio of products, expanding clinical research initiatives, and a national commercial footprint, BioStem is committed to advancing innovation in regenerative medicine.”
BSEM’s “quality management system and standard operating procedures have been reviewed and accredited by the American Association of Tissue Banks ("AATB").”
“These systems and procedures are established in compliance with current Good Tissue Practices ("cGTP") and current Good Manufacturing Practices ("cGMP").”
The company’s “portfolio of quality brands includes its Neox®, Clarix®, VENDAJE® and American Amnion™ product lines.”
The clinical results are compelling.
For instance, BSEM has “Superior Outcomes with BioRetain® Allograft in Diabetic Foot Ulcers” where “The probability of healing in the BR-AC arm was 53% while the probability of healing in the standard of care arm was 31%”.
Furthermore, “In a competitive study, the BR-AC arm required 2.7 fewer applications and 9.1 less treatment days for closure compared to the market leader”.
In the Ambulate study of the “most severe chronic wounds”, the company reported “66% closure at 26 weeks”.
Earlier this year, the company announced:
“BioStem Technologies Advances Entry into the Acute Wound Care Market with Acquisition of BioTissue Holdings’ Surgical and Wound Care Business”
Here are some of the company’s comments from this press release:
"This acquisition is a natural strategic fit that underscores BioStem's commitment to leading the field of advanced wound care. It provides an immediate foothold in hospital-based applications and expands our technology portfolio with an additional platform designed to optimize the preservation of both placental and umbilical tissue allografts," said Jason Matuszewski, CEO and Chairman of BioStem. "This acquired technology opens meaningful entry into high-value adjacent market segments, from acute surgical wounds to burns and soft-tissue repair, while creating synergies that enhance our entire product suite and diversify our revenue streams. BioTissue's broad and innovative surgical portfolio, robust pipeline, and highly skilled sales force, combined with BioStem's reach and operational strengths, uniquely position us to address patient needs across the spectrum of acute and chronic wound care. I am excited to welcome the impressive team of BioTissue employees to further our mission of delivering the most advanced wound healing technologies in the world."
The company has announced multiple accomplishments recently.
In May, the company announced:
“BioStem Technologies Reports First Quarter 2026 Financial Results”
Recent Financial and Business Highlights
“Generated net revenue of $6.1 million for the first quarter 2026
Progressed integration initiatives following the BioTissue assets acquisition including reassignment of all GPO contracts
Expanded direct sales force to 35 representatives, up from 18 at the close of the BioTissue assets acquisition
Strengthened leadership team with appointment of Katherine Gorrell as Chief Legal and Compliance Officer
Retired outstanding debt with GMA to resolve two existing promissory notes, with an aggregate principal amount of $3 million and accrued interest of $2.3M
Advanced capital markets strategy with the completion of audited financial statements for 2024 and 2025; progressing toward planned Nasdaq uplisting”
Jason Matuszewski, Chairman and CEO of BioStem stated:
"The first quarter of 2026 marked the beginning of a strategic transformation for BioStem, as we completed our acquisition of the surgical and wound care assets from BioTissue and repositioned the company as a fully integrated, hospital-focused commercial organization. To best leverage these new resources in alignment with what we see as our most attractive market opportunity, the majority of our focus is now being prioritized on the hospital market. During the quarter, we expanded our presence across hospital-based settings, increased exposure to commercially insured patients, and made strong progress on key priorities including commercial integration"
Also in May, the company announced:
“BioStem Technologies Announces $2.5 Million Private Placement Financing with its First Institutional Investor”
Jason Matuszewski, Chairman and CEO of BioStem stated:
"This transaction marks continued progress in the execution of our capital markets strategy, and, together with the previously announced debt retirement, strengthens our balance sheet" said Jason Matuszewski, Chairman and CEO of BioStem Technologies. "We expect the progress we are making toward the Nasdaq uplist and our improved capital position will provide increased flexibility to address our long-term capital needs in support of our growth plans."
In June, the company announced:
“BioStem Technologies Announces Appointment of Three New Members to its Board of Directors”
“The new independent directors strengthen the Company's board as seasoned executives bring deep expertise in life sciences commercialization, healthcare administration, and investment management”
BSEM “announced the appointment of Mark Glickman, Steven D. Sonenreich, and Rayna Lesser Hannaway to its Board of Directors, effective as of June 5, 2026. In connection with their appointment to the Board of Directors, Mr. Sonenreich has been appointed as a member of the Audit Committee and the Corporate Governance and Nominating Committee, Ms. Hannaway has been appointed as a member of the Audit Committee and the Corporate Governance and Nominating Committee and Mr. Glickman has been appointed as a member and as Chair of the Compensation Committee. Concurrently, the Company also announced that Thomas Dugan and Patrick Daly have resigned from the board, effective as of June 4, 2026. Following these changes, the Company's Board of Directors consists of seven members.”
Here are some of the company’s comments from this press release:
"We are thrilled to welcome Mark, Steven, and Rayna to the BioStem Board," said Jason Matuszewski, Chairman and CEO of BioStem Technologies. "These three industry veterans each bring unique and highly complementary expertise, from pharmaceutical commercialization, healthcare systems leadership, and capital markets experience. Their collective insights will be invaluable during our next phase of growth as we scale our business, strengthen our governance, and work toward a Nasdaq uplisting. At the same time, we also want to extend our sincere gratitude to Thomas and Patrick for their dedicated service and meaningful contributions to BioStem during their tenure as directors."
In July, the company announced:
“BioStem Technologies Announces Issuance of Four U.S. Design Patents Covering Fenestrated Human Placental Allograft Technologies”
BSEM “announced that the United States Patent and Trademark Office (USPTO) has issued four U.S. design patents covering the Company's proprietary fenestrated human placental allograft technologies.”
“The newly issued patents strengthen BioStem's intellectual property portfolio and provide additional protection for innovative allograft designs in surgical and wound care applications.”
Here are some of the company’s comments from this press release:
"These newly issued patents represent another important step in strengthening the intellectual property foundation supporting our placental-derived allograft technologies," said Jason Matuszewski, Chairman and CEO of BioStem Technologies. "Protecting the innovations behind our products helps support our long-term growth strategy while reinforcing our commitment to advancing regenerative medicine through differentiated technologies designed to improve patient care."
As the company further explains:
“The four patents further expand BioStem's growing intellectual property portfolio, which includes more than 100 patents and patent applications worldwide.”
“BioStem continues to invest in innovation across placental tissue processing, preservation technologies, and allograft designs as it develops next-generation products for wound care and surgical applications.”
“BioStem's proprietary processing technologies are designed to optimize preservation of the innate structural and biological characteristics of placental tissues, supporting their use in a variety of clinical applications, including surgical and wound care procedures.”
As the company announced on July 29, today “BioStem Technologies to Host Second Quarter 2026 Financial Results Conference Call on August 12, 2026”
Here is the full press release:
BSEM “will release its second quarter 2026 financial results on Wednesday, August 12, 2026, and will host a conference call and webcast at 4:30 PM ET.”
The webcast will feature an overview of the quarter from BioStem Technologies management. To register for the event, please click HERE.
Conference Call & Webcast Information:
Conference ID: 9695874
North America Toll-Free: (800) 715-9871
International Toll: +1 (646) 307-1963
Webcast Link: https://events.q4inc.com/attendee/199151484
Most recently, on Thursday, the company announced:
“BioStem Technologies Announces Nasdaq Uplisting”
Jason Matuszewski, Chairman and CEO of BioStem stated:
"Our uplisting to Nasdaq is an important milestone for BioStem, reflecting the significant progress we have made in strengthening our foundation, streamlining our operations, and executing on our core business strategy," said Jason Matuszewski, Chairman and CEO of BioStem Technologies. "We believe this uplisting will expand our access to capital, improve market visibility and liquidity for our shareholders, and reinforce our ability to attract exceptional talent as we continue to grow. We are deeply grateful to our partners, investors, and stakeholders for their continued support throughout this process."
BSEM could be positioned for significant upside.
Make sure to do your own due diligence.
Happy Trading!
SmallCapStocks Team
Note: We encourage all traders and investors to develop personal trading rules that you can follow and that work for you. Always protect your downside and note that we alert extremely volatile short-term opportunities. Before investing in securities, you should always consult with your financial, tax and legal advisor and never invest money you cannot afford to lose.
DISCLAIMER:
You should read and understand this disclaimer in its entirety before joining the website or email/blog list of SmallCapStocks.com (the “Publisher”). The information (collectively the “Advertisement”) disseminated by email, text or other method by the Publisher including this publication is a paid commercial advertisement and should not be relied upon for making an investment decision or any other purpose. The Publisher is engaged in the business of marketing and advertising the securities of publicly traded companies in exchange for compensation. The track record, gains, upside, and/or losses mentioned in the Advertisement, if any, should not be considered as true or accurate or be the basis for an investment. The Publisher does not verify the accuracy or completeness of any information included in the Advertisement. While the Publisher does not charge for the SMS service, standard carrier message and data rates may apply. To unsubscribe from receiving promotional text messages to your phone sent via an autodialer, using your phone reply to the sender’s phone number with the word STOP or HELP for help.
The Advertisement is not a solicitation or recommendation to buy securities of the advertised company. An offer to buy or sell securities can be made only by a disclosure document that complies with applicable securities laws and only in the states or other jurisdictions in which the security is eligible for sale. The Advertisement is not a disclosure document. The Advertisement is only a favorable snapshot of unverified information about the advertised company. An investor considering purchasing the securities, should always do so only with the assistance of his legal, tax and investment advisors. Investors should review with his or her investment advisor, tax advisor or attorney, if and to the extent available, any information concerning a potential investment at the web sites of the U.S. Securities and Exchange Commission (the "SEC") at www.sec.gov; the Financial Industry Regulatory Authority (the "FINRA") at www.FINRA.org, and relevant State Securities Administrator website and the OTC Markets website at www.otcmarkets.com. The Publisher cautions investors to read the SEC advisory to investors concerning Internet Stock Fraud at www.sec.gov/consumer/cyberfr.htm, as well as related information published by the FINRA on how to invest carefully. Investors are responsible for verifying all information in the Advertisement. As an advertiser, we do not verify any information we publish. The Advertisement should not be considered true or complete.
The Publisher does not offer investment advice or analysis, and the Publisher further urges you to consult your own independent tax, business, financial and investment advisors concerning any investment you make in securities particularly those quoted on the OTC Markets. Investing in securities is highly speculative and carries an extremely high degree of risk. You could lose your entire investment if you invest in any company mentioned in the Advertisement. You acknowledge that we are not an investment advisory service, a broker-dealer or an investment adviser and we are not qualified to act as such. You acknowledge that you will consult with your own independent, tax, financial and/or legal advisers regarding any decisions as to any company mentioned here. We have not determined if the Advertisement is accurate, correct or truthful. The Advertisement is compiled from publicly available information, which include, but are not limited to, no cost online research, magazines, newspapers, reports filed with the SEC or information furnished by way of press releases. Because all information relied upon by us in preparing an advertisement about an issuer comes from a public source, it is not reliable, and you should not assume it is accurate or complete.
Owners and operators of the Publisher expect to be compensated nine thousand dollars by bank wire transfer on 8/12/26 for the distribution of this advertisement about BSEM dated 8/12/26. The Publisher and its owners and operators hold no stocks or bonds in companies discussed in the Advertisement. Owners and operators of the Publisher own several newsletters, therefore you may receive multiple publications and emails featuring companies at different or the same time.
You are receiving this report/release because you subscribed to receive it at our website or through a third-party site. All our newsletters include an "unsubscribe" link, and you can remove yourself at any time from our newsletters by clicking on that "unsubscribe" link. You can also contact us at [email protected] to change your information at any time. By your subscription to our profiles, the viewing of this profile and/or use of our website, you have agreed and acknowledged the terms of our full disclaimer and privacy policy which can be viewed at the following link:
www.SmallCapStocks.com/Disclaimer and www.SmallCapStocks.com/Privacy-Policy
By accepting the Advertisement, you agree and acknowledge that any hyperlinks to the website of (1) a client company, (2) the party issuing or preparing the information for the company, or (3) other information contained in the Advertisement is provided only for your reference and convenience. The advertiser is not responsible for the accuracy or reliability of these external sites, nor is it responsible for the content, opinions, products or other materials on external sites or information sources. If you use, act upon or make decisions in reliance on information contained in any disseminated report/release or any hyperlink, you do so at your own risk and agree to hold us, our officers, directors, shareholders, affiliates and agents harmless. You acknowledge that you are not relying on the Publisher, and we are not liable for, any actions taken by you based on any information contained in any disseminated email or hyperlink.